Moderna Inc (MRNA)
41.77
+3.52
(+9.20%)
USD |
NASDAQ |
Nov 22, 12:17
Moderna Research and Development Expense (Quarterly): 1.137B for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.137B |
| June 30, 2024 | 1.221B |
| March 31, 2024 | 1.063B |
| December 31, 2023 | 1.406B |
| September 30, 2023 | 1.16B |
| June 30, 2023 | 1.148B |
| March 31, 2023 | 1.131B |
| December 31, 2022 | 1.211B |
| September 30, 2022 | 820.00M |
| June 30, 2022 | 710.00M |
| March 31, 2022 | 554.00M |
| December 31, 2021 | 648.00M |
| September 30, 2021 | 521.00M |
| June 30, 2021 | 421.00M |
| Date | Value |
|---|---|
| March 31, 2021 | 401.00M |
| December 31, 2020 | 759.00M |
| September 30, 2020 | 344.00M |
| June 30, 2020 | 152.00M |
| March 31, 2020 | 115.00M |
| December 31, 2019 | 117.64M |
| September 30, 2019 | 119.64M |
| June 30, 2019 | 128.30M |
| March 31, 2019 | 130.41M |
| December 31, 2018 | 150.43M |
| September 30, 2018 | 109.05M |
| June 30, 2018 | 104.48M |
| March 31, 2018 | 90.12M |
| December 31, 2017 | 117.83M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
115.00M
Minimum
Mar 2020
1.406B
Maximum
Dec 2023
751.98M
Average
734.50M
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.734B |
| Merck & Co Inc | 5.862B |
| Pfizer Inc | 2.598B |
| Novavax Inc | 87.16M |
| Vertex Pharmaceuticals Inc | 875.90M |